ATRC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
AtriCure Inc (ATRC) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock faces significant competitive headwinds, insider selling, and mixed analyst sentiment. While the company has shown revenue growth, its profitability metrics have declined sharply. Given the lack of strong positive catalysts and the bearish technical indicators, holding off on investing in ATRC is advisable for now.
The technical indicators for ATRC are bearish. The MACD is negative and contracting, RSI is neutral at 34.074, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 32.01, with key support at 30.692 and resistance at 33.328.
The company reported a 13.05% YoY revenue increase in Q4 2025, and analysts believe the company has a competitive moat with strong clinical data and product defensibility.
Insider selling has increased significantly (521.10% over the last month). Analysts have lowered price targets due to competitive threats from Edwards Lifesciences and Medtronic. Financial performance shows a sharp decline in net income (-111.28% YoY) and EPS (-112.12% YoY). Technical indicators are bearish, and there are no recent positive trading trends or news.
In Q4 2025, revenue increased by 13.05% YoY to $140.5M, but net income dropped by -111.28% YoY to $1.756M, and EPS fell by -112.12% YoY to $0.04. Gross margin improved slightly to 74.97%, up 0.59% YoY.
Analyst sentiment is mixed. While Canaccord, UBS, and Citizens maintain Buy/Outperform ratings with lowered price targets ($53, $55, $52), Oppenheimer downgraded the stock to Perform, citing long-term competitive risks. JPMorgan also downgraded the stock to Neutral with a price target of $36, citing competitive threats from Edwards Lifesciences and Medtronic.
